Realtime | Geld | Brief | Zeit |
---|---|---|---|
2,450 | 2,550 | 21.01. |
Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
13.01. | Sequana Medical NV: Press release: Transparency Notification from Shareholders | 254 | GlobeNewswire (Europe) | Transparency Notification from Shareholders
Ghent, Belgium - 13 January 2025 - Sequana Medical NV (Euronext Brussels: SEQUA) (the "Company" or "Sequana
Medical"), a pioneer in the treatment... ► Artikel lesen | |
07.01. | Sequana Medical NV: Press release: Six Month Data from alfapump Pivotal POSEIDON Study in Treatment of Recurrent or Refractory Ascites due to Liver Cirrhosis Published in American Journal of Gastroenterology | 1.248 | GlobeNewswire (Europe) | Six Month Data from alfapump® Pivotal POSEIDON Study in Treatment of Recurrent or Refractory Ascites due to Liver Cirrhosis Published in American Journal of Gastroenterology
alfapump® system is... ► Artikel lesen | |
06.01. | Sequana Medical NV: Press release: Sequana Medical Announces Key Opinion Leader (KOL) Webinar to Discuss alfapump US Commercial Roll-Out on January 8th at 15:00 CET / 09:00 EST | 351 | GlobeNewswire (Europe) | Sequana Medical Announces Key Opinion Leader (KOL) Webinar to Discuss alfapump® US Commercial Roll-Out on January 8th at 15:00 CET / 09:00 EST
Webinar to discuss US commercial roll-out following... ► Artikel lesen | |
03.01. | FDA approves Sequana Medical's Alfapump for ascites treatment | 2 | PharmaTimes | ||
23.12.24 | Sequana Medical: FDA Approves Alfapump For Treatment Of R/R Ascites Due To Liver Cirrhosis | 16 | RTTNews | ||
23.12.24 | Sequana Medical NV: Press release: Sequana Medical Announces US FDA Approval of alfapump for the Treatment of Recurrent or Refractory Ascites due to Liver Cirrhosis | 644 | GlobeNewswire (Europe) | Sequana Medical Announces US FDA Approval of alfapump® for the Treatment of Recurrent or Refractory Ascites due to Liver Cirrhosis
alfapump® is the first US approved active implantable medical device... ► Artikel lesen | |
20.12.24 | Sequana Medical NV: Press Release: Sequana Medical announces results of Extraordinary General Meeting of Shareholders and update on Convertible Financing | 405 | GlobeNewswire (Europe) | Sequana Medical announces results of Extraordinary General Meeting of Shareholders and update on Convertible Financing
Ghent, Belgium - 20 December 2024
- Sequana Medical NV (Euronext Brussels:... ► Artikel lesen | |
06.12.24 | Sequana Medical NV: Press Release: Sequana Medical announces decision of major shareholders to invest in Second Tranche of Convertible Bridge Loan | 333 | GlobeNewswire (Europe) | SEQUANA MEDICAL ANNOUNCES DECISION OF MAJOR SHAREHOLDERS TO INVEST IN SECOND TRANCHE OF CONVERTIBLE BRIDGE LOAN
Ghent, Belgium, 6 December 2024 - Sequana Medical NVand here).
For more information... ► Artikel lesen | |
SEQUANA MEDICAL Aktie jetzt für 0€ handeln | |||||
02.12.24 | Sequana Medical NV: Press Release: Sequana Medical announces update on second tranche of convertible bridge loan | 173 | GlobeNewswire (Europe) | SEQUANA MEDICAL ANNOUNCES UPDATE ON SECOND TRANCHE OF CONVERTIBLE BRIDGE LOAN
Ghent, Belgium - 2 December 2024 - Sequana Medical NV (Euronext Brussels: SEQUA) (the "Company" or "Sequana Medical")... ► Artikel lesen | |
27.11.24 | Sequana Medical NV: Press Release: Publication in Kidney Medicine Highlights Benefits of DSR 2.0 for Sequana Medical's Direct Sodium Removal Heart Failure Program and Board Composition Update | 503 | GlobeNewswire (Europe) | Publication in Kidney Medicine Highlights Benefits of DSR 2.0 for Sequana Medical's Direct Sodium Removal Heart Failure Program and Board Composition Update
More efficient sodium and fluid removal... ► Artikel lesen | |
26.11.24 | Sequana Medical NV: Press Release: Transparency Notification from Shareholders | 333 | GlobeNewswire (Europe) | Transparency Notification from Shareholders
Ghent, Belgium - 26 November 2024 - Sequana Medical NV (Euronext Brussels: SEQUA) (the "Company" or "Sequana
Medical"), a pioneer in the treatment... ► Artikel lesen | |
20.11.24 | Sequana Medical NV: Press Release: Sequana Medical announces Extraordinary General Meeting of Shareholders on 20 December 2024 | 441 | GlobeNewswire (Europe) | Sequana Medical announces Extraordinary General Meeting of Shareholders on 20 December 2024
Ghent, Belgium - 20 November 2024
- Sequana Medical NV (Euronext Brussels: SEQUA) (the "Company"... ► Artikel lesen | |
18.11.24 | Sequana Medical NV: Press Release: Sequana Medical Announces Strong 24-Month Results from POSEIDON Study at AASLD The Liver Meeting in San Diego; US PMA alfapump approval expected before end of Q1 2025 | 294 | GlobeNewswire (Europe) | Sequana Medical Announces Strong 24-Month Results from POSEIDON Study at AASLD The Liver Meeting® in San Diego; US PMA alfapump approval expected before end of Q1 2025
alfapump was very effective... ► Artikel lesen | |
14.11.24 | Sequana Medical NV: Press Release: Sequana Medical Announces New Share Capital Amount and New Number of Shares | 227 | GlobeNewswire (Europe) | SEQUANA MEDICAL ANNOUNCES NEW SHARE CAPITAL AMOUNT
AND NEW NUMBER OF SHARES
Ghent, Belgium, 14 November 2024 - Sequana Medical NV
(Euronext Brussels: SEQUA) (the "Company" or "Sequana
Medical")... ► Artikel lesen | |
23.10.24 | Sequana Medical NV: Press release: SEQUANA MEDICAL ANNOUNCES ADDITIONAL CONVERTIBLE FINANCING OF UP TO EUR 1.0 MILLION FROM EXISTING INVESTORS | 371 | GlobeNewswire (Europe) | SEQUANA MEDICAL ANNOUNCES ADDITIONAL CONVERTIBLE FINANCING OF UP TO EUR 1.0 MILLION FROM EXISTING INVESTORS
Ghent, Belgium, 23 October 2024 - Sequana Medical NV (Euronext Brussels: SEQUA) (the "Company"... ► Artikel lesen | |
21.10.24 | Sequana Medical NV: Press release: SEQUANA MEDICAL ANNOUNCES NEW SHARE CAPITAL AMOUNT AND NEW NUMBER OF SHARES | 260 | GlobeNewswire (Europe) | PRESS RELEASEREGULATED INFORMATION21 October 2024, 06:00 p.m. CEST
SEQUANA MEDICAL ANNOUNCES NEW SHARE CAPITAL AMOUNT AND NEW NUMBER OF SHARES
Ghent, Belgium, 21 October 2024 - Sequana Medical... ► Artikel lesen | |
10.10.24 | Sequana Medical NV: Press release: Transparency Notification from Shareholders | 351 | GlobeNewswire (Europe) | Transparency Notification from Shareholders
Ghent, Belgium - 10 October 2024 - Sequana Medical NV (Euronext Brussels: SEQUA) (the "Company" or "Sequana
Medical"), a pioneer in the treatment... ► Artikel lesen | |
01.10.24 | Sequana Medical NV: Sequana Medical announces H1 2024 results and provides business update | 599 | GlobeNewswire (Europe) | PRESS RELEASEREGULATED INFORMATION - INSIDE INFORMATION30 September 2024, 23:55 CEST
Sequana Medical announces H1 2024 results and provides business update
alfapump® - US FDA approval anticipated... ► Artikel lesen | |
01.10.24 | Sequana Medical NV: SEQUANA MEDICAL ANNOUNCES CONVERTIBLE FINANCING OF UP TO EUR 6.1 MILLION FROM MAJOR SHAREHOLDERS | 556 | GlobeNewswire (Europe) | THIS ANNOUNCEMENT IS NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, JAPAN, SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE TO DO SO WOULD BE PROHIBITED... ► Artikel lesen | |
09.08.24 | Sequana Medical NV: Press release: Transparency Notification from Shareholders | 409 | GlobeNewswire (Europe) | Transparency Notification from Shareholders
Ghent, Belgium - 9 August 2024 - Sequana Medical NV (Euronext Brussels: SEQUA) (the "Company" or "Sequana
Medical"), a pioneer in the treatment of... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
FRESENIUS | 36,210 | -0,47 % | Fresenius SE Aktie: Zeichen stehen auf Gewinn | Die Fresenius SE-Aktie zeigt sich am Handelstag in robuster Verfassung und verzeichnet eine positive Entwicklung im XETRA-Handel. Das Wertpapier konnte im Tagesverlauf um 0,6 Prozent zulegen und erreichte... ► Artikel lesen | |
SIEMENS HEALTHINEERS | 53,78 | +3,22 % | Siemens Healthineers-Aktie: Kurs klettert leicht (53,42 €) | Am deutschen Aktienmarkt liegt das Wertpapier von Siemens Healthineers aktuell im Plus. Die Aktie kostete zuletzt 53,42 Euro. Die Aktie von Siemens Healthineers verzeichnet gegenwärtig einen Wertanstieg... ► Artikel lesen | |
CARL ZEISS MEDITEC | 48,800 | +1,41 % | JPMORGAN stuft CARL ZEISS MEDITEC AG auf 'Underweight' | NEW YORK (dpa-AFX Analyser) - Die US-Bank JPMorgan hat die Einstufung für Carl Zeiss Meditec mit einem Kursziel von 40 Euro auf "Underweight" belassen. Das erste Geschäftsquartal dürfte mau ausfallen... ► Artikel lesen | |
ECKERT & ZIEGLER | 48,280 | -0,12 % | AKTIONÄR-Tipp Telix Pharma: Zulassung - darum profitiert auch Eckert & Ziegler | In den USA wird das radiopharmazeutische Diagnostik-Produkt Illuccix bereits regelrecht aus den Regalen gerissen. Entwickler Telix Pharma kann den Top-Seller nun auch in Europa auf den Markt bringen.... ► Artikel lesen | |
DRAEGERWERK | 55,90 | +2,01 % | HAUCK AUFHÄUSER INVESTMENT BANKING stuft Draegerwerk auf 'Buy' | HAMBURG (dpa-AFX Analyser) - Hauck Aufhäuser Investment Banking hat die Einstufung für Drägerwerk mit einem Kursziel von 86 Euro auf "Buy" belassen. Bei Drägerwerk-Aktien müsse man ausnahmsweise der... ► Artikel lesen | |
MEDTRONIC | 84,79 | -0,06 % | Medtronic Appoints Thierry Pieton As CFO | WASHINGTON (dpa-AFX) - Medtronic Plc (MDT), a healthcare technology company, said on Tuesday that it has appointed Thierry Pieton as its Chief Financial Officer with effect from March 3. Pieton... ► Artikel lesen | |
UNITEDHEALTH | 503,70 | +0,02 % | AKTIE IM FOKUS: UnitedHealth sehr schwach nach Zahlen - Erholungstrend gefährdet | NEW YORK (dpa-AFX) - Mit Kursabschlägen von mehr als 5 Prozent haben die Anleger von UnitedHealth am Donnerstag die Geschäftszahlen des US-Krankenversicherers quittiert. Im nur leicht schwächeren Leitindex... ► Artikel lesen | |
GERRESHEIMER | 67,05 | +2,52 % | EQS-PVR: Gerresheimer AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution | EQS Voting Rights Announcement: Gerresheimer AG
Gerresheimer AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of... ► Artikel lesen | |
THERMO FISHER | 550,70 | +0,16 % | MedMira mit zweiter Zulassung!: MedMira erhält von Health Canada Zulassung für Reveal® G4 Rapid HIV-1/2 Test | ||
STRATEC | 34,000 | -1,16 % | DEUTSCHE BANK RESEARCH stuft STRATEC BIOMEDICAL SYSTEMS AG auf 'Hold' | FRANKFURT (dpa-AFX Analyser) - Deutsche Bank Research hat die Einstufung für Stratec mit einem Kursziel von 39 Euro auf "Hold" belassen. Analyst Jan Koch schrieb in seinem am Montag vorliegenden Kommentar... ► Artikel lesen | |
ESSILORLUXOTTICA | 250,80 | -0,12 % | EssilorLuxottica Aktie: Blühende Aussichten genießen! | Der französisch-italienische Brillenkonzern EssilorLuxottica verzeichnet einen deutlichen Kursanstieg an den Börsen. Der aktuelle Handelstag brachte einen Zuwachs von 2,3 Prozent, wodurch die Aktie... ► Artikel lesen | |
HIMS & HERS HEALTH | 28,680 | +0,31 % | Hims & Hers Health Unusual Options Activity | ||
ALCON | 84,33 | +3,11 % | Alcon to Present at 2025 Annual J.P. Morgan Healthcare Conference | Regulatory News:
Alcon (SIX/NYSE: ALC) CEO David Endicott will present at the 2025 J.P. Morgan Healthcare Conference on Tuesday, January 14, 2025, at 4:30 p.m. PST.
A live webcast of the conference... ► Artikel lesen | |
RESMED | 238,90 | +0,42 % | Should you buy CSL and ResMed shares in January? | ||
HEALWELL AI | 1,250 | -0,79 % | HEALWELL AI schließt die Eigenkapitaltranche im Wert von 25,5 Millionen $ seiner aufgestockten Bought-Deal-Finanzierung ab | - HEALWELL hat die Eigenkapitaltranche seiner zuvor angekündigten aufgestockten Bought-Deal-Finanzierung in Höhe von 55 Millionen $ abgeschlossen und damit einen Bruttoerlös
von 25,5... ► Artikel lesen |